OK - So I asked Chat GPT to rewrite this linked article that was...

OK - So I asked Chat GPT to rewrite this linked article that was shared by Heyline in another thread: https://www.projecttopics.com/science-releases/8418-two-new-powerful-small-molecules-may-be-able-to-kill-cancers-that-other-therapies-cant/
The request of ChatGPT was to dumb it down for a Herald Sun article, to help with PR (honestly what are PR doing). Also added a few changes, but reads well and could just as easily generate a Media Release for the likes of a nightly news item on TV.

Melbourne-based Race Oncology is making significant strides in the fight against cancer. A team of scientists at City of Hope have discovered that two small molecules, known as CS1 (Bisantrene) and CS2, may suppress tumour growth in various cancers, including breast, brain, and pancreatic cancers, as well as acute myeloid leukemia. These two inhibitors, from a databank of over 260,000 tested, target a protein called "fat mass and obesity-associated protein" (FTO), which plays a crucial role in the development and progression of cancer.
FTO regulates cancer stem cells and immune evasion, promoting the growth, self-renewal, metastasis, and immune escape of cancer cells.The scientists found that the two FTO inhibitor compounds they created had potent anti-tumour effects and significantly improved overall survival in mice with acute myeloid leukemia or solid tumours, such as breast cancer.
Chen and his team at City of Hope, a leading cancer research and treatment centre, have been researching RNA modification in cancer for eight years, and are at the forefront of precision medicine, developing personalized treatments.Many cancer patients either do not respond to current treatments such as chemotherapy, targeted therapy, or immunotherapy, or they respond initially but relapse later due to cancer-regenerating stem cells and the escape of cancer cells from our immune surveillance. By modifying FTO or using small molecules to inhibit it, scientists can interrupt the supply chain that enables cancer to develop and progress.CS1 (Bisantrene) and CS2 prevent FTO from connecting with target messenger RNAs, including cancer-causing genes, as well as immune checkpoint genes. According to Jianjun Chen, the cancer inhibitors developed are at least ten times more effective in killing acute myeloid leukemia cells than several previously reported FTO inhibitors.The National Institutes of Health (NIH) has already funded the next step: The Chen lab is working to further optimize CS1 (Bisantrene) and CS2 to develop improved FTO inhibitor compounds that are more efficacious with minimal side effects for humans. Bisantrene, one of the two compounds, is owned by Race Oncology, an Australian company. It has been tested in multiple clinical trials for other objectives, and Race Oncology believes that this research has access to a freeway entrance that will fast track it into clinical trials.